First-in-Human Study on Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Escalating Doses of HEC88473, a Novel Dual GLP-1 and FGF21 Receptor Agonist in Healthy and Obese Chinese Subjects
Hong Zhang, Qianqian Li, Hong Chen, Lingfeng Guo, Jing Li, Can Xie, Jiangyu Yan, Yanhua Ding
Springer Nature ·
2025-04-03
· DOI 10.1007/s40259-025-00715-3
The publisher did not provide an abstract — full text is available via the link below.
Hong Zhang, Qianqian Li, Hong Chen, Lingfeng Guo, Jing Li, Can Xie et al. First-in-Human Study on Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Escalating Doses of HEC88473, a Novel Dual GLP-1 and FGF21 Receptor Agonist in Healthy and Obese Chinese Subjects. // BioDrugs. – 2025. – DOI: 10.1007/s40259-025-00715-3. – URL: https://doi.org/10.1007/s40259-025-00715-3
Hong Zhang, Qianqian Li, Hong Chen, Lingfeng Guo, Jing Li, Can Xie, Jiangyu Yan, & Yanhua Ding (2025). First-in-Human Study on Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Escalating Doses of HEC88473, a Novel Dual GLP-1 and FGF21 Receptor Agonist in Healthy and Obese Chinese Subjects. BioDrugs. https://doi.org/10.1007/s40259-025-00715-3
Hong Zhang, et al. “First-in-Human Study on Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Escalating Doses of HEC88473, a Novel Dual GLP-1 and FGF21 Receptor Agonist in Healthy and Obese Chinese Subjects.” BioDrugs, 2025. doi:10.1007/s40259-025-00715-3.
@article{Zhang2025,
title = {First-in-Human Study on Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Escalating Doses of HEC88473, a Novel Dual GLP-1 and FGF21 Receptor Agonist in Healthy and Obese Chinese Subjects},
author = {Zhang, Hong and Li, Qianqian and Chen, Hong and Guo, Lingfeng and Li, Jing and Xie, Can and Yan, Jiangyu and Ding, Yanhua},
journal = {BioDrugs},
year = {2025},
doi = {10.1007/s40259-025-00715-3},
url = {https://doi.org/10.1007/s40259-025-00715-3}
}